Chemokines and angiogenesis

Current Opinion in Rheumatology

Volumn 13, Issue 3, 2001, Pages 202-208

  Szekanecz, Zoltan ^a   Koch, Alisa E ^b  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CHEMOKINE; BETA CHEMOKINE; CHEMOKINE RECEPTOR; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78;

ANGIOGENESIS; DISEASE COURSE; HUMAN; LEUKOCYTE; MONOCYTE; NEOVASCULARIZATION (PATHOLOGY); NEUTROPHIL; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

ANTIBODIES; ARTHRITIS, RHEUMATOID; CHEMOKINES; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CHEMOKINE;

EID: 0035002342     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200105000-00009     Document Type: Review

References (60)

1. 1 Szekanecz Z, Strieter RM, Kunkel SL, et al.: Chemokines in rheumatoid arthritis. Springer Semin Immunopathol 1998, 20:115-132.
2. 2 Koch AE, Kunkel SL, Strieter RM: Chemokines in arthritis. In Chemokines in Disease, Edited by Koch AE, Strieter RM, Austin, TX: RG Landes, 1996:103-116.
3. 3 Harris ED: Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med 1990, 332:1277-1287.
4. 4 Bazan JF, Bacon KB, Hardiman G, et al.: A new class of membrane bound chemokine with a CX3C motif. Nature 1997, 385:640-644.
5. 5 Mackay CR: Chemokines: what chemakine is that? Curr Biol 1997, 7:R384-R386.
6. 6 Taub DD: C-C Chemokines: an overview. In Chemokines in Disease. Edited by Koch AE, Strieter RM. Austin, TS: RG Landes, 1996:27-54.
7. 7 Walz A, Kunkel SL, Strieter RM: C-X-C chemokines: an overview. In Chemokines in Disease. Edited by Koch AE, Strieter RM. Austin, TX; RG Landes, 1996:1-25.
8. 3 Wooley PH, Schaefer C, Whalen JD, et al.: A peptide sequence from platelet factor 4 (CT-112) is effective in the treatment of type II collagen induced arthritis in mice. J Rheumatol 1997, 24:890-898.
9. 9 Hosaka S, Akahoshi T, Wada C, et al.: Expression of the chemokine super-family in rheumatoid arthritis. Clin Exp Immunol 1994, 97:451-457.
10. 10 Koch AE, Kunkel SL, Harlow LA, et al.: Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest 1992, 90:772-779.
11. 11 Koch AE, Kunkel SL, Harlow LA, et al.: Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. J Clin Invest. 1994, 94:1012-1018.
12. 12 Rathanaswami P, Hachicha M, Sadick M, et al.: Expression of the cytokine RANTES in human rheumatoid synovial fibroblasts: differential regulation of RANTES and interleukin-8 genes by inflammatory cytokines. J Biol Chem 1993, 268:5834-5839.
13. 13 Szeksnecz Z, Halloran MM, Volin MV, et al.: Temporal expression of inflammatory cytokines and chemokines in rat adjuvant-induced arthritis. Arthritis Rheum 2000, 43:1266-1277. This study gives a differentiation between "early" and "late" cytokines and chemokines playing a role in the pathogenesis of rat adjuvant-induced arthritis, a model for human rheumatoid arthritis.
14. 14 Thornton S, Duwel LE, Boivin GP, et al.: Association of the course of collagen-induced arthritis with distinct patterns of cytokine and chemokine messenger RNA expression. Arthritis Rheum 1999, 42:1109-1118.
15. 15 Loetscher P, Dewald B, Baggiolini M, et al.: Monocyte chemoattractant protein 1 and interleukin 8 production by rheumatoid synoviocytes: effects of anti-rheumatic drugs. Cytokine 1994, 6:162-170.
16. 16 Seitz M, Dewald B, Gerber N, et al.: Enhanced production of neutrophil-activating peptide-1/interleukin-8 in rheumatoid arthritis. J Clin Invest 1991, 87:463-469.
17. 17 Volin MV, Harlow LA, Woods JM, et al.: Treatment with sulfasalazine or sulfapyridine, but not 5-aminosalicyclic acid, inhibits basic fibroblast growth factor-induced endothelial cell chemotaxis. Arthritis Rheum 1999, 42:1927-1935.
18. 18 Taylor PC, Peters AM, Paleolog E, et al.: Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum 2000, 43:38-47. This very interesting article on therapeutics shows that anti-TNF-treatment of rheumatoid arthritis results in diminished leukocyte ingress into the synovium associated with suppressed synovial chemokine production.
19. 19 Koch AE, Kunkel SL, Shah MR, et al.: Growth related gene product alpha: a chemotactic cytokine for neutrophils in rheumatoid arthritis. J Immunol 1995, 155:3660-3666.
20. 20 Halloran MM, Woods JM, Strieter RM, et al.: The role of an epithelial neutrophil-activating peptide-78-like protein in rat adjuvant-induced arthritis. J Immunol 1999, 162:7492-7500.
21. 21 Gong JH, Ratkay LG, Waterfield JD, et al.: An antagonist of manocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. J Exp Med 1997, 186:131-137.
22. 22 Loetscher P, Uguccioni M, Bordoli L, et al.: CCR5 is characteristic of Th1 lymphocytes. Nature 1998, 391:344-345.
23. 23 Qin S, Rottman JB, Myers P, et al.: The chemokine receptors CXCR3 and CCR5 mark subsets of T cells with a homing predilection for certain inflammatory sites. J Clin Invest 1998, 101:746-750.
24. 24 Gomez-Reino JJ, Pablos JL, Carreira PE, et al.: Association of rheumatoid arthritis with a functional chemokine receptor, CCR5. Arthritis Rheum 1999, 42:989-992.
25. 25 Wedderburn LR, Robinson N, Patel A, et al.: Selective recruitment of polarized T cells expressing CCR5 and CXCR3 to the inflamed joints of children with juvenile idiopathic arthritis. Arthritis Rheum 2000, 43:765-774.
26. 26 Brenchley PE: Angiogenesis in inflammatory joint disease: a target for therapeutic intervention [editorial]. Clin Exp Immunol 2000, 121:426-429. A crucial introduction to the role of angiogenesis in rheumatoid arthritis with clinical aspects.
27. 27 Walsh DA: Angiogenesis and arthritis. Rheumatology (Oxford) 1999, 38:103-112. Another very concise review of angiogenesis in arthritis.
28. 28 Paleolog EM, Fava RA: Angiogenesis in rheumatoid arthritis: implications for future therapeutic strategies. Springer Semin Immunopathol 1998, 20:73-94.
29. 29 Szekanecz Z, Koch AE: Angiogenesis in rheumatoid arthritis. In Angiogenesis in Health and Disease. Edited by Rubanyi GM. New York, Basel: Marcel Dekker, 2000:429-450.
30. 30 Szekanecz Z, Szegedi G, Koch AE: Angiogenesis in rheumatoid arthritis. J Invest Med 1998, 46:27-41.
31. 31 Koch AE: Angiogenesis: implications for rheumatoid arthritis. Arthritis Rheum 1998, 41:951-962.
32. 32 Colville-Nash PR, Scott DL: Angiogenesis in rheumatoid arthritis: pathogenic and therapeutic implications. Ann Rheum Dis 1992, 51:919-925.
33. 33 Szekanecz Z, Halloran MM, Haskell CJ, et al.: Mediators of angiogenesis: the role of cellular adhesion molecules. Trends Glycosci Glycotechnol 1999, 58:73-93.
34. 34 Grant DS, Kleinman HK, Goldberg ID, et al.: Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA 1993, 90:1937-1941.
35. 35 Koch AE, Harlow LA, Haines GK, et al.: Vascular endothelial growth factor: a cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994, 152:4149-4156.
36. 36 Sato N, Beitz JG, Kato J, et al.: Platelet-derived growth factor indirectly stimulates angiogenesis in vitro. Am J Pathol 1993, 142:1119-1130.
37. 37 Angiolillo AL, Kanegane H, Sgadari C, et al.: Interleukin-15 promotes angiogenesis in vivo. Biochem Biophys Res Commun 1997, 233:231-237.
38. 38 Auerbach W, Auerbach R: Angiogenesis inhibition: a review. Pharmacol Ther 1994, 63:265-311.
39. 39 Moore BB, Keane MP, Addison CL, et al: CXC chemokine modulation of angiogenesis: the importance of balance between angiogenic and angiostatic members of the family. J Invest Med 1998, 46:113-120. An important review on the role of angiogenic and angiostatic C-X-C chemokines in neovascularization. This study discusses the role of the ELR motif in angiogenesis.
40. 40 Keane MP, Strieter RM: The role of CXC chemokines in the regulation of angiogenesis. Chem Immunol 1999, 72:86-101. Review of the role of chemokines in angiogenesis.
41. 41 Fava RA, Olsen NJ, Postlethwaite AE, et al.: Transforming growth factor β1 (TGF-β1) induced neutrophil recruitment to synovial tissues: implications for TGF-β-driven synovial inflammation and hyperplasia. J Exp Med 1991, 173:1121-1132.
42. 42 Brennan FM, Field M, Chu CQ, et al.: Cytokine expression in rheumatoid arthritis. Br J Rheumatol 1991, 30:76-80.
43. 43 Hamilton JA, Waring PM, Filonzi EL: Induction of leukemia inhibitory factor in human synovial fibroblasts by IL-1 and tumor necrosis factor-a. J Immunol 1993, 150:1496-1502.
44. 44 Taraboletti G, Belotti D, Giavazzi R: Thrombospondin modulates basic fibroblast growth factor activities on endothelial cells. EXS 1991, 59:210-213.
45. 45 Szekanecz Z, Haines GK, Lin TR, et al.: Differential distribution of intercellular adhesion molecules (ICAM-1, ICAM-2, and ICAM-3) and the MS-1 antigen in normal and diseased human synovia: their possible pathogenetic and clinical significance in rheumatoid arthritis. Arthritis Rheum 1994, 37:221-231.
46. 46 Johnson B, Haines GK, Harlow LA, et al.: Adhesion molecule expression in human synovial tissues. Arthritis Rheum 1993, 36:137-146.
47. 47 Koch AE, Turkiewicz W, Harlow LA, et al.: Soluble E-selectin in arthritis. Clin Immunol Immunopathol 1993, 69:29-35.
48. 48 Wellicome SM, Kapahi P, Mason JC, et al.: Detection of a circulating form of vascular cell adhesion molecule-1: raised levels in rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol 1993, 92:412-418.
49. 49 Koch AE, Cho M, Burrows J, et al.: Inhibition of production of macrophage-derived angiogenic activity by the anti-rheumatic agents gold sodium thiomalate and auranofin. Biochem Biophys Res Commun 1988, 154:205-212.
50. 50 Oliver SJ, Banquerigo ML, Brahn E: Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol. Cell Immunol 1994, 157:291-299.
51. 51 Addison CL, Arenberg DA, Morris SB, et al.: The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis. Hum Gene Ther 2000, 11:247-261.
52. 52 Keane MP, Belperio JA, Arenberg DA, et al.: IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. J Immunol 1999, 163:5686-5692.
53. 53 Rinaldi N, Schwarz-Eywill M, Weis D, et al.: Increased expression of integrins on fibroblast-like synoviocytes from rheumatoid arthritis in vitro correlates with enhanced binding to extracellular matrix proteins. Ann Rheum Dis 1991, 56:45-51.
54. 54 Salcedo R, Wasserman K, Young HA, et al.: Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: in vivo neovascularization induced by stromal-derived factor-1 alpha. Am J Pathol 1999, 164:1125-1135.
55. 55 Peichev M, Naiyer AJ, Pereira D, et al.: Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000, 95:952-958. A very interesting study showing that there are CD34 positive endothelial precursor cells in the blood. These cells express the VEGF receptor and use the CXCR4 chemokine receptor to migrate toward the chemokine SDF-1.
56. 56 Rempel SA, Dudas S, Ge S, Gutierrez JA.: Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. Clin Cancer Res 2000, 6:102-111. An important paper on the interactions between the SDF-1 chemokine and its receptor.
57. 57 Salcedo R, Ponce ML, Young HA, et al.: Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000, 96:34-40. This study is the first to show the role of a C-C chemokine in angiogenesis. Furthermore, the role of the chemokine receptor CCR2 and its ligand MCP-1 on endothelial cells is suggested.
58. 58 Vicari AP, Ait-Yahia S, Chemin K, et al.: Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J Immunol 2000, 165:1992-2000 This study suggests the angiostatic role of the chemokine SLC in the inhibition of tumor progression.
59. 59 Volin MV, Woods JM, Amin AM, et al.: Fractalkine a novel angiogenic chemokine in rheumatoid arthritis. Arthritis Rheum 1999, 42(Suppl 9):78.
60. 60 Strieter RM, Polverini PJ, Kunkel SL, et al.: The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995, 270:27348-27357.